Menu Search
Equities

Roche Holding AG

RO:SWX

Roche Holding AG

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CHF)252.80
  • Today's Change2.60 / 1.04%
  • Shares traded159.33k
  • 1 Year change-17.65%
  • Beta--
Data delayed at least 15 minutes, as of May 31 2024 16:30 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

  • Revenue in CHF (TTM)58.72bn
  • Net income in CHF11.50bn
  • Incorporated1966
  • Employees103.61k
  • Location
    Roche Holding AGGrenzacherstrasse 124BASEL 4002SwitzerlandCHE
  • Phone+41 9 732354295
  • Websitehttps://www.roche.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		ROG:SWX since
announced		Transaction
value
LumiraDx International LtdAnnounced29 Dec 202329 Dec 2023Announced-4.72%--
LumiraDx Group LtdAnnounced29 Dec 202329 Dec 2023Announced-4.72%295.00m
Carmot Therapeutics IncDeal completed04 Dec 202304 Dec 2023Deal completed-3.59%3.10bn
Data delayed at least 15 minutes, as of May 31 2024 16:35 BST.

Institutional shareholders

5.68%Per cent of shares held by top holders
HolderShares% Held
APG Asset Management NVas of 31 Dec 20221.49m1.39%
The Vanguard Group, Inc.as of 09 May 20241.14m1.07%
UBS Asset Management Switzerland AGas of 07 May 2024764.67k0.72%
BlackRock Fund Advisorsas of 09 May 2024690.45k0.65%
Z�rcher Kantonalbank (Investment Management)as of 28 Mar 2024588.55k0.55%
Credit Suisse Asset Management (Schweiz) AGas of 29 Feb 2024484.04k0.45%
Vontobel Asset Management AGas of 30 Apr 2024237.16k0.22%
BlackRock Advisors (UK) Ltd.as of 09 May 2024232.64k0.22%
BlackRock Asset Management Schweiz AGas of 08 May 2024225.00k0.21%
Geode Capital Management LLCas of 30 May 2024206.22k0.19%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.